• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vaxxas wins $3.7M award to support needle-free typhoid vaccine tech

August 25, 2023 By Sean Whooley

Vaxxas micropatch vaccine COVID-19
Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]
Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device.

The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the skin as a patch, the system rapidly delivers vaccines to immune cells below the skin surface.

HD-MAP offers improved thermostability, potentially reducing the cost and complexity of cold-chain distribution and storage. It also potentially requires less training to administer and could even lead to self-administration.

Global charitable foundation, Wellcome, made the award to conduct investigational new drug-enabling and first-in-human studies. The company expects to complete the project within two years.

It aims to accelerate the delivery of a potentially second-generation typhoid vaccine, based on SKYTyphoid, an approved typhoid conjugate. SK Bioscience, Vaxxas’ collaborator in the project, and the International Vaccine Institute developed the formulation. The developers formulated the vaccine candidate for more stability at higher temperatures than required for needle and syringe vaccination.

“We are excited to be initiating this important work with Wellcome and SK bioscience to leverage our HD-MAP vaccine platform to potentially enhance typhoid vaccination,” said David L. Hoey, President and CEO of Vaxxas. “We believe our HD-MAP can play a critical role in extending the global reach of typhoid conjugate vaccines, and make a significant difference to the lives of many.”

Vaxxas also has programs underway for its technology to deliver COVID-19 and influenza vaccines. The company raised $23 million at the end of last year as well to support its platform.

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Technology Tagged With: Vaxxas

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS